Paul Richardson, MD, Dana-Farber Cancer Institute, Boston, MA, briefly summarizes his presentation at COMy 2022 which focused on the value of immunotherapies at first relapse in multiple myeloma. Dr Richardson mentions the importance of improving outcomes in newly diagnosed patients and the promise of personalizing treatment approaches with novel immunotherapies to provide patients with the best options. This interview took place at the 8th World Congress on Controversies in Multiple Myeloma (COMy) 2022, held in Paris, France.